


WHAT IS CLAIMED IS:

1. A compound of Formula (I):



5 wherein L is a linker connecting the carbon atom of the phenyl ring to the nitrogen of the -NH- moiety, wherein L is

- (i) a single bond,
(ii) -(C₁₋₆ alkyl)-, which is optionally substituted with
-C(=O)N(R^aR^b),
10 (iii) -(C₀₋₃ alkyl)-C=C-(C₁₋₃ alkyl)-,
(iv) -(C₀₋₃ alkyl)-C≡C-(C₁₋₃ alkyl)-, or
(v) -(C₀₋₆ alkyl)-(C₃₋₆ cycloalkyl)-(C₀₋₆ alkyl)-;

15 R^{1a}, R^{1b}, and R^{1c} are each independently -H, halogen, -C₁₋₆ alkyl, or -C₁₋₆ haloalkyl;

R^{2a} and R^{2b} are each independently:

- (1) -H,
(2) -C₁₋₆ alkyl, optionally substituted with one or more substituents each
20 of which is independently halogen, -OH, -O-C₁₋₆ alkyl, -O-C₁₋₆ haloalkyl, -CN, -NO₂, -N(R^aR^b), -C(=O)N(R^aR^b), -C(=O)R^a,
-CO₂R^a, -OCO₂R^a, -S(O)_nR^a, -SO₂N(R^aR^b), -N(R^a)C(=O)R^b,
-N(R^a)CO₂R^b, -N(R^a)SO₂R^b, or -N(R^a)SO₂N(R^aR^b),
(3) -C₁₋₆ alkyl substituted with one substituent which is -C₃₋₈ cycloalkyl,
25 aryl, or heteroaryl, wherein:
(a) the cycloalkyl is optionally substituted with one or more substituents each of which is independently halogen, -OH, -C₁₋₆ alkyl,
-C₁₋₆ alkyl-O-C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -O-C₁₋₆ alkyl, -O-C₁₋₆ haloalkyl, or phenyl;

(b) the aryl is an aromatic carbocyclic ring or an aromatic carbocyclic fused ring system, wherein the aryl is optionally substituted with one or more substituents each of which is independently halogen, -OH, -C₁₋₆ alkyl, -C₁₋₆ alkyl-O-C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -O-C₁₋₆ alkyl, -O-C₁₋₆ haloalkyl, -CN, -NO₂, -N(R^aR^b), -C₁₋₆ alkyl-N(R^aR^b), -C(=O)N(R^aR^b), -C₁₋₆ alkyl-C(=O)N(R^aR^b), -C(=O)R^a, -C₁₋₆ alkyl-C(=O)R^a, -CO₂R^a, -C₁₋₆ alkyl-CO₂R^a, -OCO₂R^a, -C₁₋₆ alkyl-OCO₂R^a, -S(O)_nR^a, -C₁₋₆ alkyl-S(O)_nR^a, -SO₂N(R^aR^b), -C₁₋₆ alkyl-SO₂N(R^aR^b), -N(R^a)SO₂R^b, -C₁₋₆ alkyl-N(R^a)SO₂R^b, -N(R^a)C(=O)R^b, -C₁₋₆ alkyl-N(R^a)C(=O)R^b, -N(R^a)CO₂R^b, -C₁₋₆ alkyl-N(R^a)CO₂R^b, -N(R^a)SO₂N(R^aR^b), -C₁₋₆ alkyl-N(R^a)SO₂N(R^aR^b), phenyl, -C₁₋₆ alkyl-phenyl, -O-phenyl, -C₁₋₆ alkyl-O-phenyl, HetA, or -C₁₋₆ alkyl-HetA; wherein each HetA is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally fused with a benzene ring; and wherein each HetA is optionally substituted with one or more substituents each of which is independently -C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -O-C₁₋₆ alkyl, -O-C₁₋₆ haloalkyl, oxo, or -CO₂R^a; and

(c) the heteroaryl is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms or a 9- or 10-membered bicyclic heteroaromatic ring system containing from 1 to 6 heteroatoms, wherein the heteroatoms in the heteroaryl are independently selected from N, O and S; and wherein the heteroaryl is optionally substituted with one or more substituents each of which is independently halogen, -OH, -C₁₋₆ alkyl, -C₁₋₆ alkyl-O-C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -O-C₁₋₆ alkyl, -O-C₁₋₆ haloalkyl, -N(R^aR^b), -C₁₋₆ alkyl-N(R^aR^b), -C(=O)N(R^aR^b), -C₁₋₆ alkyl-C(=O)N(R^aR^b), -C(=O)R^a, -C₁₋₆ alkyl-C(=O)R^a, -CO₂R^a, -C₁₋₆ alkyl-CO₂R^a, -OCO₂R^a, -C₁₋₆ alkyl-OCO₂R^a, -S(O)_nR^a, -C₁₋₆ alkyl-S(O)_nR^a, -SO₂N(R^aR^b), -C₁₋₆ alkyl-SO₂N(R^aR^b), -N(R^a)SO₂R^b, -C₁₋₆ alkyl-N(R^a)SO₂R^b, -N(R^a)C(=O)R^b, -C₁₋₆ alkyl-N(R^a)C(=O)R^b, -N(R^a)CO₂R^b, -C₁₋₆ alkyl-N(R^a)CO₂R^b, phenyl, -C₁₋₆ alkyl-phenyl, or oxo;

- (4) -O-C₁₋₆ alkyl, optionally substituted with one or more substituents each of which is independently halogen, -OH, -O-C₁₋₆ alkyl, -O-C₁₋₆ haloalkyl, -S(O)_nR^a, -N(R^a)-CO₂R^b, or -C(=O)N(R^aR^b),
- (5) -OH,
- 5 (6) halo,
- (7) -NO₂,
- (8) -CN,
- (9) -C(=O)R^a,
- (10) -CO₂R^a,
- 10 (11) -S(O)_nR^a,
- (12) -SO₂N(R^aR^b),
- (13) -N(R^aR^b),
- (14) -C(=O)N(R^aR^b),
- (15) -N(R^a)SO₂R^b,
- 15 (16) -OC(=O)N(R^aR^b),
- (17) -N(R^a)C(=O)N(R^aR^b),
- (18) -N(R^a)-C₁₋₆ alkyl-C(=O)N(R^aR^b),
- (19) -N(R^a)-C(=O)-C₁₋₆ alkyl-N(R^aR^b),
- (20) -N(R^a)C(=O)-C(=O)N(R^aR^b),
- 20 (21) -OCO₂R^a,
- (22) -N(R^a)-SO₂N(R^aR^b),
- (23) -N(R^a)-SO₂-C₁₋₆ alkyl-N(R^aR^b),
- (24) -N(R^a)C(=O)R^b,
- (25) -N(R^a)CO₂R^b,
- 25 (26) -S-C₁₋₆ alkyl-C(=O)N(R^aR^b), or
- (27) -N(SO₂R^a)-C₁₋₆ alkyl-C(=O)N(R^aR^b);

R³ is

- (1) -H,
- 30 (2) -C₁₋₆ alkyl, optionally substituted with one or more substituents each of which is independently halogen, -OH, -O-C₁₋₆ alkyl, -O-C₁₋₆ haloalkyl, -CN, -NO₂, -N(R^aR^b), -C(=O)N(R^aR^b), -OC(=O)N(R^aR^b), -N(R^a)C(=O)N(R^aR^b), -N(R^a)-C₁₋₆ alkyl-C(=O)N(R^aR^b), -N(R^a)-C(=O)-C₁₋₆ alkyl-N(R^aR^b), -N(R^a)C(=O)-C(=O)N(R^aR^b),

-C(=O)Ra, -CO₂Ra, -OCO₂Ra, -S(O)_nRa, -SO₂N(RaRb),
 -N(Ra)-SO₂N(RaRb), -N(Ra)-SO₂-C₁₋₆ alkyl-N(RaRb),
 -N(Ra)C(=O)Rb, -N(Ra)CO₂Rb, -N(Ra)SO₂Rb, or -G-C₁₋₆
 alkyl-C(=O)N(RaRb) wherein G is O or S or N(SO₂Ra),

5 with the proviso that none of the following substituents is
 attached to the carbon in the -C₁₋₆ alkyl group that is attached to the
 ring nitrogen: -OH, -O-C₁₋₆ alkyl, -O-C₁₋₆ haloalkyl, -NO₂,
 -N(RaRb), -OC(=O)N(RaRb), -N(Ra)C(=O)N(RaRb), -N(Ra)-C₁₋₆
 alkyl-C(=O)N(RaRb), -N(Ra)-C(=O)-C₁₋₆ alkyl-N(RaRb),
 10 -N(Ra)C(=O)-C(=O)N(RaRb), -OCO₂Ra, -N(Ra)-SO₂N(RaRb),
 -N(Ra)-SO₂-C₁₋₆ alkyl-N(RaRb), -N(Ra)C(=O)Rb, -N(Ra)CO₂Rb,
 -N(Ra)SO₂Rb, or -G-C₁₋₆ alkyl-C(=O)N(RaRb) wherein G is O or
 N(SO₂Ra),

(3) -C₁₋₆ alkyl substituted with one of:

- 15 (i) -R^k,
 (ii) -S(O)_n-R^k,
 (iii) -S(O)_n-C₁₋₆ alkyl-R^k,
 (iv) -C(=O)-R^k,
 (v) -C(=O)-C₁₋₆ alkyl-R^k,
 20 (vi) -C(=O)N(Ra)-R^k, or
 (vii) -C(=O)N(Ra)-C₁₋₆ alkyl-R^k,

(4) -C₂₋₆ alkyl substituted with one of:

- (i) -O-R^k,
 (ii) -O-C₁₋₆ alkyl-R^k,
 25 (iii) -N(Ra)-R^k,
 (iv) -N(Ra)-C₁₋₆ alkyl-R^k,
 (v) -N(Ra)C(=O)-R^k,
 (vi) -N(Ra)C(=O)-C₁₋₆ alkyl-R^k,

30 with the proviso that the substituent is not attached to the
 carbon in the -C₂₋₆ alkyl group that is attached to the ring nitrogen,

(5) -S(O)_nRa,

(6) -SO₂N(RaRb),

(7) -C₂₋₆ alkenyl, optionally substituted with one substituent which is
 -C(=O)-N(RaRb) or -R^k,

- (8) -C₂₋₅ alkynyl, optionally substituted with one substituent which is
-CH₂N(R^aR^b), -CH₂OR^a, or -R^k,
(9) -R^k,
(10) -S(O)_n-C₁₋₆ alkyl-R^k,
5 (11) -N(R^a)C(=O)-R^k, or
(12) -N(R^a)C(=O)-C₁₋₆ alkyl-R^k;

each of R⁴ and R⁵ is independently

- (1) -H,
10 (2) -C₁₋₆ alkyl, optionally substituted with one or more substituents each
of which is independently halogen, -OH, -O-C₁₋₆ alkyl, -O-C₁₋₆
haloalkyl, -CN, -NO₂, -N(R^aR^b), -C(=O)N(R^aR^b), -OC(=O)N(R^aR^b),
-N(R^a)C(=O)N(R^aR^b), -N(R^a)-C₁₋₆ alkyl-C(=O)N(R^aR^b),
-N(R^a)-C(=O)-C₁₋₆ alkyl-N(R^aR^b), -N(R^a)C(=O)-C(=O)N(R^aR^b),
15 -C(=O)R^a, -CO₂R^a, -OCO₂R^a, -S(O)_nR^a, -SO₂N(R^aR^b),
-N(R^a)-SO₂N(R^aR^b), -N(R^a)-SO₂-C₁₋₆ alkyl-N(R^aR^b),
-N(R^a)C(=O)R^b, -N(R^a)CO₂R^b, -N(R^a)SO₂R^b, or -G-C₁₋₆
alkyl-C(=O)N(R^aR^b) wherein G is O or S or N(SO₂R^a),
(3) -SO₂N(R^aR^b), or
20 (4) -C₁₋₆ alkyl-R^m;

each R^a and R^b is independently -H, -C₁₋₆ alkyl, or -C₃₋₈ cycloalkyl;

R^k is a carbocycle or a heterocycle;

each R^m is independently a carbocycle or a heterocycle;

each carbocycle is independently (i) a C₃ to C₈ monocyclic, saturated or unsaturated
ring, (ii) a C₇ to C₁₂ bicyclic ring system, or (iii) a C₁₁ to C₁₆ tricyclic ring system,
30 wherein each ring in (ii) or (iii) is independent of or fused to the other ring or rings
and each ring is saturated or unsaturated; wherein the carbocycle is optionally
substituted with one or more substituents each of which is independently

- (1) halogen,
(2) -OH,

- 5 (3) -C₁₋₆ alkyl, optionally substituted with one or more substituents each of which is independently -OH, -O-C₁₋₆ alkyl, -O-C₁₋₆ haloalkyl, -CN, -NO₂, -N(R^aR^b), -C(=O)N(R^aR^b), -C(=O)R^a, -CO₂R^a, -OCO₂R^a, -S(O)_nR^a, -SO₂N(R^aR^b), -N(R^a)SO₂R^b, -N(R^a)C(=O)R^b, -N(R^a)CO₂R^b, -N(R^a)SO₂R^b, phenyl, -O-phenyl, or HetB,
- (4) -C₁₋₆ haloalkyl,
- (5) -O-C₁₋₆ alkyl,
- (6) -O-C₁₋₆ haloalkyl,
- 10 (7) -CN,
- (8) -NO₂,
- (9) -N(R^aR^b),
- (10) -C(=O)N(R^aR^b),
- (11) -C(=O)R^a,
- (12) -CO₂R^a,
- 15 (13) -OCO₂R^a,
- (14) -S(O)_nR^a,
- (15) -N(R^a)SO₂R^b,
- (16) -SO₂N(R^aR^b),
- (17) -N(R^a)C(=O)R^b,
- 20 (18) -N(R^a)CO₂R^b,
- (19) phenyl,
- (20) -O-phenyl, or
- (21) HetB,

25 wherein each HetB is independently a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally fused with a benzene ring; and wherein each HetB is optionally substituted with one or more substituents each of which is independently -C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -O-C₁₋₆ alkyl, -O-C₁₋₆ haloalkyl, oxo, or -CO₂R^a;

30

each heterocycle is independently (i) a 4- to 8-membered, saturated or unsaturated monocyclic ring, (ii) a 7- to 12-membered bicyclic ring system, or (iii) an 11 to 16-membered tricyclic ring system; wherein each ring in (ii) or (iii) is independent of or

fused to the other ring or rings and each ring is saturated or unsaturated; the monocyclic ring, bicyclic ring system, or tricyclic ring system contains from 1 to 6 heteroatoms independently selected from N, O and S; and wherein any one or more of the nitrogen and sulfur heteroatoms is optionally oxidized, and any one or more of the nitrogen heteroatoms is optionally quaternized; wherein the heterocycle is optionally substituted with one or more substituents each of which is independently

- (1) halogen,
- (2) -OH,
- (3) -C₁₋₆ alkyl, optionally substituted with one or more substituents each of which is independently -OH, -O-C₁₋₆ alkyl, -CN, -NO₂, -N(R^aR^b), -C(=O)N(R^aR^b), -C(=O)R^a, -CO₂R^a, -S(O)_nR^a, -N(R^a)SO₂R^b, -SO₂N(R^aR^b), -N(R^a)C(=O)R^b, -N(R^a)CO₂R^b, phenyl, -O-phenyl, or HetC,
- (4) -C₁₋₆ haloalkyl,
- (5) -O-C₁₋₆ alkyl,
- (6) -O-C₁₋₆ haloalkyl,
- (7) -CN,
- (8) -NO₂,
- (9) -N(R^aR^b),
- (10) -C(=O)N(R^aR^b),
- (11) -C(=O)R^a,
- (12) -CO₂R^a,
- (13) -OCO₂R^a,
- (14) -S(O)_nR^a,
- (15) -N(R^a)SO₂R^b,
- (16) -SO₂N(R^aR^b),
- (17) -N(R^a)C(=O)R^b,
- (18) -N(R^a)CO₂R^b,
- (19) phenyl,
- (20) -O-phenyl,
- (21) HetC, or
- (22) oxo;

wherein each HetC is independently a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally

fused with a benzene ring; and wherein each HetC is optionally substituted with one or more substituents each of which is independently -C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -O-C₁₋₆ alkyl, -O-C₁₋₆ haloalkyl, oxo, or -CO₂R^a; and

5

each n is independently an integer equal to 0, 1 or 2;

or a pharmaceutically acceptable salt thereof.

10

2. The compound according to claim 1, wherein R^{1a} and R^{1c} are both -H; and R^{1b} is fluoro;

or a pharmaceutically acceptable salt thereof.

15

3. The compound according to claim 1, wherein R^{2a} and R^{2b} are each independently:

- (1) -H,
- (2) -C₁₋₄ alkyl, optionally substituted with 1 or 2 substituents each of which is independently -OH, -O-C₁₋₄ alkyl, -O-CF₃, -CN, -NO₂, -N(R^aR^b), -C(=O)N(R^aR^b), -C(=O)R^a, -CO₂R^a, -OCO₂R^a, -S(O)_nR^a, -SO₂N(R^aR^b), -N(R^a)C(=O)R^b, -N(R^a)CO₂R^b, or -N(R^a)SO₂R^b,
- (3) -CF₃,
- (4) -C₁₋₄ alkyl substituted with one of -C₃₋₆ cycloalkyl, aryl, or heteroaryl, wherein:

20

the cycloalkyl is optionally substituted with 1 or 2 substituents each of which is independently fluoro, chloro, bromo, -OH, -C₁₋₄ alkyl, -(CH₂)₁₋₂-O-C₁₋₄ alkyl, -CF₃, -O-C₁₋₄ alkyl, -OCF₃, or phenyl;

25

the aryl is phenyl, naphthyl, anthryl, or phenanthryl; wherein the aryl is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, chloro, bromo, -OH, -C₁₋₄ alkyl, -(CH₂)₁₋₂-O-C₁₋₄ alkyl, -CF₃, -O-C₁₋₄ alkyl, -OCF₃, -CN, -NO₂, -N(R^aR^b), -C₁₋₄ alkyl-N(R^aR^b), -C(=O)N(R^aR^b), -C₁₋₄ alkyl-C(=O)N(R^aR^b), -C(=O)R^a, -C₁₋₄ alkyl-C(=O)R^a, -CO₂R^a,

35

-C₁₋₄ alkyl-CO₂R^a, -OCO₂R^a, -C₁₋₄ alkyl-OCO₂R^a, -S(O)_nR^a, -C₁₋₄ alkyl-S(O)_nR^a, -SO₂N(R^aR^b), -C₁₋₄ alkyl-SO₂N(R^aR^b), -N(R^a)SO₂R^b, -C₁₋₄ alkyl-N(R^a)SO₂R^b, -N(R^a)C(=O)R^b, -C₁₋₄ alkyl-N(R^a)C(=O)R^b, -N(R^a)CO₂R^b, -C₁₋₄ alkyl-N(R^a)CO₂R^b, -N(R^a)SO₂N(R^aR^b), -C₁₋₄ alkyl-N(R^a)SO₂N(R^aR^b), phenyl, -C₁₋₄ alkyl-phenyl, -O-phenyl, -C₁₋₄ alkyl-O-phenyl, HetA, or -C₁₋₄ alkyl-HetA; wherein each HetA is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally fused with a benzene ring; and wherein each HetA is optionally substituted with from 1 to 4 substituents each of which is independently -C₁₋₄ alkyl, -CF₃, -O-C₁₋₄ alkyl, -OCF₃, oxo, or -CO₂R^a; and

the heteroaryl is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; wherein the heteroaryl is optionally substituted with 1 or 2 substituents each of which is independently fluoro, chloro, bromo, -OH, -C₁₋₄ alkyl, -(CH₂)₁₋₂-O-C₁₋₄ alkyl, -CF₃, -O-C₁₋₄ alkyl, -OCF₃, -N(R^aR^b), -C₁₋₄ alkyl-N(R^aR^b), -C(=O)N(R^aR^b), -C₁₋₄ alkyl-C(=O)N(R^aR^b), -C(=O)R^a, -C₁₋₄ alkyl-C(=O)R^a, -CO₂R^a, -C₁₋₄ alkyl-CO₂R^a, -OCO₂R^a, -C₁₋₄ alkyl-OCO₂R^a, -S(O)_nR^a, -SO₂N(R^aR^b), -C₁₋₄ alkyl-S(O)_nR^a, -SO₂N(R^aR^b), -N(R^a)SO₂R^b, -C₁₋₄ alkyl-N(R^a)SO₂R^b, -N(R^a)C(=O)R^b, -C₁₋₄ alkyl-N(R^a)C(=O)R^b, -N(R^a)CO₂R^b, -C₁₋₄ alkyl-N(R^a)CO₂R^b, phenyl, -C₁₋₄ alkyl-phenyl, or oxo;

(5) -O-C₁₋₆ alkyl, optionally substituted with 1 or 2 substituents each of which is independently -OH, -O-C₁₋₄ alkyl, -OCF₃, -S(O)_nR^a, or -NH-CO₂R^a, or -C(=O)N(R^aR^b),

(6) -OCF₃,

(7) -OH,

(8) fluoro, chloro, or bromo,

(9) -NO₂,

(10) -CN,

(11) -C(=O)R^a,

(12) -CO₂R^a,

- (13) $-S(O)_nR^a$,
 (14) $-SO_2N(R^aR^b)$,
 (15) $-N(R^aR^b)$,
 (16) $-C(=O)N(R^aR^b)$,
 5 (17) $-N(R^a)SO_2R^b$, or
 (18) $-N(R^a)C(=O)R^b$;

or a pharmaceutically acceptable salt thereof.

- 10 4. The compound according to claim 3, wherein R^{2a} and R^{2b} are each independently:
- (1) $-H$,
 (2) $-C_{1-4}$ alkyl,
 (3) $-C_{1-2}$ alkyl substituted with one substituent which is $-OH$, OCH_3 ,
 15 $-CN$, $-N(R^aR^b)$, $-C(=O)N(R^aR^b)$, $-C(=O)R^a$, $-CO_2R^a$, $-SR^a$, $-SO_2R^a$,
 $-SO_2N(R^aR^b)$, $-N(R^a)C(=O)R^b$, $-N(R^a)CO_2R^b$, or $-N(R^a)SO_2R^b$,
 (4) $-CF_3$,
 (5) $-CH_2$ -cyclopropyl,
 (6) $-CH_2$ -phenyl, wherein the phenyl is optionally substituted with from 1
 20 to 3 substituents each of which is independently fluoro, chloro, bromo,
 $-C_{1-4}$ alkyl, $-CH_2OCH_3$, $-CF_3$, $-O-C_{1-4}$ alkyl, $-OCF_3$, $-CN$,
 $-N(R^aR^b)$, $-C(=O)N(R^aR^b)$, $-C(=O)R^a$, $-CO_2R^a$, or $-S(O)_nR^a$;
 (7) $-CH_2$ -heteroaryl, wherein the heteroaryl is pyridyl, pyrrolyl, pyrazinyl,
 25 pyrimidinyl, pyridazinyl, thienyl, furanyl, imidazolyl, pyrazolyl,
 triazolyl, tetrazolyl, oxazolyl, isooxazolyl, oxadiazolyl, thiazolyl,
 isothiazolyl, or thiadiazolyl; and wherein the heteroaryl is optionally
 substituted with 1 or 2 substituents each of which is independently
 fluoro, chloro, bromo, $-C_{1-4}$ alkyl, $-O-C_{1-4}$ alkyl, or oxo,
 (8) $-O-C_{1-4}$ alkyl,
 30 (9) $-OCF_3$,
 (10) $-OH$
 (11) fluoro, chloro, or bromo,
 (12) $-NO_2$,
 (13) $-CN$,

- (14) $-\text{C}(=\text{O})\text{R}^{\text{a}}$,
- (15) $-\text{CO}_2\text{R}^{\text{a}}$,
- (16) $-\text{S}(\text{O})_n\text{R}^{\text{a}}$,
- (17) $-\text{SO}_2\text{N}(\text{R}^{\text{a}}\text{R}^{\text{b}})$,
- 5 (18) $-\text{N}(\text{R}^{\text{a}}\text{R}^{\text{b}})$,
- (19) $-\text{C}(=\text{O})\text{N}(\text{R}^{\text{a}}\text{R}^{\text{b}})$,
- (20) $-\text{N}(\text{R}^{\text{a}})\text{SO}_2\text{R}^{\text{b}}$, or
- (21) $-\text{N}(\text{R}^{\text{a}})\text{C}(=\text{O})\text{R}^{\text{b}}$;

10 each R^{a} and R^{b} is independently $-\text{H}$ or $-\text{C}_{1-4}$ alkyl;

or a pharmaceutically acceptable salt thereof.

15 5. The compound according to claim 4, wherein $\text{R}^{2\text{a}}$ and $\text{R}^{2\text{b}}$ are each independently:

- (1) $-\text{H}$,
- (2) $-\text{C}_{1-4}$ alkyl,
- (3) $-\text{CF}_3$,
- (4) fluoro, chloro, or bromo,
- 20 (5) $-\text{SO}_2-\text{C}_{1-4}$ alkyl,
- (6) $-\text{S}-\text{C}_{1-4}$ alkyl,
- (7) $-\text{SO}_2\text{N}(-\text{C}_{1-4} \text{ alkyl})_2$,
- (8) $-\text{C}(=\text{O})\text{N}(-\text{C}_{1-4} \text{ alkyl})_2$,
- (9) $-\text{NHSO}_2-\text{C}_{1-4}$ alkyl,
- 25 (10) $-\text{N}(-\text{C}_{1-4} \text{ alkyl})\text{SO}_2-\text{C}_{1-4}$ alkyl,
- (11) $-\text{NHC}(=\text{O})-\text{C}_{1-4}$ alkyl,
- (12) $-\text{N}(-\text{C}_{1-4} \text{ alkyl})\text{C}(=\text{O})-\text{C}_{1-4}$ alkyl, or
- (13) $-\text{C}(=\text{O})\text{NH}(-\text{C}_{1-4} \text{ alkyl})$;

30 or a pharmaceutically acceptable salt thereof.

6. The compound according to claim 5, wherein one of $\text{R}^{2\text{a}}$ and $\text{R}^{2\text{b}}$ is $-\text{H}$, and the other of $\text{R}^{2\text{a}}$ and $\text{R}^{2\text{b}}$ is as defined in claim 5;

or a pharmaceutically acceptable salt thereof.

7. The compound according to claim 6, wherein one of R^{2a} and R^{2b} is -H, and the other of R^{2a} and R^{2b} is:

- 5 (1) -H,
- (2) -SO₂CH₃,
- (3) -SO₂CH₂CH₃,
- (4) -S-CH₃,
- (5) -S-CH₂CH₃, or
- 10 (6) -C(=O)NH(CH₃);

or a pharmaceutically acceptable salt thereof.

8. The compound according to claim 1, wherein R³ is:

- 15 (1) -H,
- (2) -C₁₋₄ alkyl, optionally substituted with one substituent which is
-O-C₁₋₄ alkyl, -CN, -N(R^aR^b), -C(=O)N(R^aR^b), -OC(=O)N(R^aR^b),
-N(R^a)C(=O)N(R^aR^b), -N(R^a)C(=O)CH₂N(R^aR^b),
-N(R^a)C(=O)-C(=O)N(R^aR^b), -C(=O)R^a, -CO₂R^a, -S(O)_nR^a,
20 -SO₂N(R^aR^b), -N(R^a)CO₂R^b, -N(R^a)-SO₂N(R^aR^b),
-N(R^a)-SO₂CH₂N(R^aR^b), or -N(R^a)SO₂R^b,

with the proviso that none of the following substituents is attached to the carbon in the -C₁₋₄ alkyl group that is attached to the ring nitrogen: -O-C₁₋₄ alkyl, -N(R^aR^b), -OC(=O)N(R^aR^b),

- 25 -N(R^a)C(=O)N(R^aR^b), -N(R^a)-C(=O)-CH₂N(R^aR^b),
-N(R^a)C(=O)-C(=O)N(R^aR^b), -N(R^a)CO₂R^b, -N(R^a)-SO₂N(R^aR^b),
-N(R^a)-SO₂-CH₂N(R^aR^b), or -N(R^a)SO₂R^b,

- (3) -C₁₋₄ alkyl-R^k,
- (4) -C₁₋₄ alkyl-C(=O)-R^k, or
- 30 (5) -CH₂₋₄ alkyl-N(R^a)-C(=O)-R^k, with the proviso that the substituent is not attached to the carbon in the -C₂₋₄ alkyl group that is attached to the ring nitrogen;
wherein R^k is:

(i) phenyl, which is optionally substituted with from 1 to 3 substituents each of which is independently halogen, -C₁₋₄ alkyl, -C₁₋₄ haloalkyl, -O-C₁₋₄ alkyl, or -O-C₁₋₄ haloalkyl,

(ii) a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteratoms selected from N, O and S, wherein the saturated heterocyclic ring is optionally substituted with from 1 to 3 substituents each of which is independently -C₁₋₄ alkyl or oxo, or

(iii) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteratoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from 1 to 3 substituents each of which is independently halogen, -C₁₋₄ alkyl, or -O-C₁₋₄ alkyl;

or a pharmaceutically acceptable salt thereof.

9. The compound according to claim 8, wherein R³ is:

- (1) -H,
- (2) -C₁₋₄ alkyl,
- (3) -(CH₂)₂₋₃-O-C₁₋₄ alkyl,
- (4) -(CH₂)₂₋₃-N(-C₁₋₄ alkyl)₂,
- (5) -(CH₂)₁₋₃-C(=O)N(-C₁₋₄ alkyl)₂,
- (6) -(CH₂)₂₋₃-OC(=O)N(-C₁₋₄ alkyl)₂,
- (7) -(CH₂)₂₋₃-N(-C₁₋₄ alkyl)C(=O)N(-C₁₋₄ alkyl)₂,
- (8) -(CH₂)₂₋₃-N(-C₁₋₄ alkyl)C(=O)-CH₂N(-C₁₋₄ alkyl)₂,
- (9) -(CH₂)₂₋₃-N(-C₁₋₄ alkyl)C(=O)-C(=O)N(-C₁₋₄ alkyl)₂,
- (10) -(CH₂)₁₋₃-CO₂-C₁₋₄ alkyl,
- (11) -(CH₂)₁₋₃-S(O)_n-C₁₋₄ alkyl,
- (12) -(CH₂)₁₋₃-SO₂N(-C₁₋₄ alkyl)₂,
- (13) -(CH₂)₂₋₃-N(-C₁₋₄ alkyl)-CO₂-C₁₋₄ alkyl,
- (14) -(CH₂)₂₋₃-N(-C₁₋₄ alkyl)-SO₂N(-C₁₋₄ alkyl)₂,
- (15) -(CH₂)₂₋₃-N(-C₁₋₄ alkyl)-SO₂CH₂N(-C₁₋₄ alkyl)₂,
- (16) -(CH₂)₂₋₃-N(-C₁₋₄ alkyl)-SO₂-C₁₋₄ alkyl,
- (17) -(CH₂)₁₋₃-R^k,
- (18) -(CH₂)₁₋₃-C(=O)-R^k, or
- (19) -(CH₂)₂₋₃-N(-C₁₋₄ alkyl)-C(=O)-R^k;

or a pharmaceutically acceptable salt thereof.

10. The compound according to claim 1, wherein each of R⁴ and R⁵ is independently:

- 5 (1) -H,
(2) -C₁₋₄ alkyl, optionally substituted with one substituent which is -CN, -N(R^aR^b), -C(=O)N(R^aR^b), -C(=O)R^a, -CO₂R^a, -S(O)_nR^a, -SO₂N(R^aR^b), or -N(R^a)SO₂R^b, or
(3) -C₁₋₄ alkyl-R^m,
10 wherein each R^m is independently:
(i) phenyl, which is optionally substituted with from 1 to 3 substituents each of which is independently halogen, -C₁₋₄ alkyl, -C₁₋₄ haloalkyl, -O-C₁₋₄ alkyl, or -O-C₁₋₄ haloalkyl,
(ii) a 5- or 6-membered saturated heterocyclic ring containing from
15 1 to 4 heteratoms selected from N, O and S, wherein the saturated heterocyclic ring is optionally substituted with from 1 to 3 substituents each of which is independently -C₁₋₄ alkyl or oxo, or
(iii) a 5- or 6-membered heteroaromatic ring containing from 1 to 4
20 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from 1 to 3 substituents each of which is independently halogen, -C₁₋₄ alkyl, or -O-C₁₋₄ alkyl;

or a pharmaceutically acceptable salt thereof.


25 11. The compound according to claim 10, wherein R⁴ and R⁵ are both -H;

or a pharmaceutically acceptable salt thereof.

30 12. The compound according to claim 1, wherein L is CH₂;

or a pharmaceutically acceptable salt thereof.

13. A compound of Formula (II):



wherein:

5 R1b is -H, fluoro, chloro, bromo, -C1-4 alkyl, or -CF3;

R2a is:

- (1) -H,
- (2) -C1-4 alkyl,
- 10 (3) -CF3,
- (4) fluoro, chloro, or bromo,
- (5) -SO2-C1-4 alkyl,
- (6) -S-C1-4 alkyl,
- (7) -SO2N(RaRb),
- 15 (8) -N(Ra)SO2-C1-4 alkyl, or
- (9) -C(=O)N(RaRb);

R3 is:

- (1) -H,
- 20 (2) -C1-4 alkyl, optionally substituted with one substituent which is
 -O-C1-4 alkyl, -CN, -N(RaRb), -C(=O)N(RaRb), -OC(=O)N(RaRb),
 -N(Ra)C(=O)N(RaRb), -N(Ra)C(=O)CH2N(RaRb),
 -N(Ra)C(=O)-C(=O)N(RaRb), -C(=O)Ra, -CO2Ra, -S(O)nRa,
 -SO2N(RaRb), -N(Ra)CO2Rb, -N(Ra)-SO2N(RaRb),
 25 -N(Ra)-SO2CH2N(RaRb), or -N(Ra)SO2Rb,

with the proviso that none of the following substituents is attached to the carbon in the -C1-4 alkyl group that is attached to the ring nitrogen: -O-C1-4 alkyl, -N(RaRb), -OC(=O)N(RaRb), -N(Ra)C(=O)N(RaRb), -N(Ra)-C(=O)-CH2N(RaRb),

-N(R^a)C(=O)-C(=O)N(R^aR^b), -N(R^a)CO₂R^b, -N(R^a)-SO₂N(R^aR^b),
 -N(R^a)-SO₂-CH₂N(R^aR^b), or -N(R^a)SO₂R^b,

(3) -C₁₋₄ alkyl-R^k,

(4) -C₁₋₄ alkyl-C(=O)-R^k, or

5 (5) -C₂₋₄ alkyl-N(R^a)-C(=O)-R^k, with the proviso that the substituent is not attached to the carbon in the -C₂₋₄ alkyl group that is attached to the ring nitrogen;

wherein R^k is:

10 (i) phenyl, which is optionally substituted with from 1 to 3 substituents each of which is independently halogen, -C₁₋₄ alkyl, -C₁₋₄ haloalkyl, -O-C₁₋₄ alkyl, or -O-C₁₋₄ haloalkyl,

(ii) a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteratoms selected from N, O and S, wherein the saturated heterocyclic ring is optionally substituted with from 1 to 3 substituents each of which is
 15 independently -C₁₋₄ alkyl or oxo, or

(iii) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteratoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from 1 to 3 substituents each of which is independently halogen, -C₁₋₄ alkyl, or -O-C₁₋₄ alkyl;

20

each R^a and R^b is independently -H or -C₁₋₄ alkyl; and

n is an integer equal to zero, 1 or 2;

25 or a pharmaceutically acceptable salt thereof.

14. The compound according to claim 13, wherein:

R^{1b} is fluoro, chloro, bromo, methyl, or ethyl;

30

R^{2a} is:

(1) -H,

(2) methyl or ethyl,

(3) fluoro,

- (4) -SO₂-C₁₋₄ alkyl,
 (5) -S-C₁₋₄ alkyl,
 (6) -SO₂N(-C₁₋₄ alkyl)₂,
 (7) -NH-SO₂-C₁₋₄ alkyl,
 5 (8) -N(-C₁₋₄ alkyl)SO₂-C₁₋₄ alkyl, or
 (9) -C(=O)NH(-C₁₋₄ alkyl);

R³ is:

- 10 (1) -H,
 (2) -C₁₋₄ alkyl,
 (3) -(CH₂)₂₋₃-O-C₁₋₄ alkyl,
 (4) -(CH₂)₂₋₃-N(-C₁₋₄ alkyl)₂,
 (5) -(CH₂)₁₋₃-C(=O)N(-C₁₋₄ alkyl)₂,
 (6) -(CH₂)₂₋₃-N(-C₁₋₄ alkyl)C(=O)N(-C₁₋₄ alkyl)₂,
 15 (7) -(CH₂)₂₋₃-N(-C₁₋₄ alkyl)C(=O)-C(=O)N(-C₁₋₄ alkyl)₂,
 (8) -(CH₂)₁₋₃-CO₂-C₁₋₄ alkyl,
 (9) -(CH₂)₁₋₃-S(O)_n-C₁₋₄ alkyl,
 (10) -(CH₂)₁₋₃-SO₂N(-C₁₋₄ alkyl)₂,
 (11) -(CH₂)₂₋₃-N(-C₁₋₄ alkyl)-SO₂N(-C₁₋₄ alkyl)₂,
 20 (12) -(CH₂)₂₋₃-N(-C₁₋₄ alkyl)-SO₂-C₁₋₄ alkyl,
 (13) -(CH₂)₁₋₃-R^k,
 (14) -(CH₂)₁₋₃-C(=O)-R^k, or
 (15) -(CH₂)₂₋₃-N(R^a)-C(=O)-R^k;

25 or a pharmaceutically acceptable salt thereof.

15. The compound according to claim 14, wherein:

R^{1b} is fluoro;

30

R^{2a} is:

- (1) -H,
 (2) fluoro,
 (3) -SO₂-C₁₋₄ alkyl,

- (4) -S-C₁₋₄ alkyl,
 (5) -SO₂N(-C₁₋₄ alkyl)₂,
 (6) -NHSO₂-C₁₋₄ alkyl,
 (7) -N(-C₁₋₄ alkyl)SO₂-C₁₋₄ alkyl, or
 (8) -C(=O)NH(-C₁₋₄ alkyl);

R³ is:

- (1) -H,
 (2) -C₁₋₄ alkyl,
 (3) -(CH₂)₂₋₃-O-C₁₋₄ alkyl,
 (4) -(CH₂)₂₋₃-N(-C₁₋₂ alkyl)₂,
 (5) -(CH₂)₁₋₃-C(=O)N(-C₁₋₂ alkyl)₂,
 (6) -(CH₂)₂₋₃-N(-C₁₋₂ alkyl)C(=O)N(-C₁₋₂ alkyl)₂,
 (7) -(CH₂)₂₋₃-N(-C₁₋₂ alkyl)C(=O)-C(=O)N(-C₁₋₂ alkyl)₂,
 (8) -(CH₂)₁₋₃-S(O)_n-C₁₋₂ alkyl,
 (9) -(CH₂)₁₋₃-SO₂N(-C₁₋₂ alkyl)₂,
 (10) -(CH₂)₂₋₃-N(-C₁₋₂ alkyl)-SO₂N(-C₁₋₂ alkyl)₂,
 (11) -(CH₂)₂₋₃-N(-C₁₋₂ alkyl)-SO₂-C₁₋₂ alkyl,
 (12) -(CH₂)₁₋₃-R^k, or
 (13) -(CH₂)₁₋₃-C(=O)-R^k;

or a pharmaceutically acceptable salt thereof.




16. The compound according to claim 15, wherein R^k is:





- (i) phenyl which is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, chloro, bromo, -C₁₋₄ alkyl, -CF₃, -O-C₁₋₄ alkyl, or -OCF₃;
- (ii) a saturated heterocyclic ring selected from the group consisting of piperidinyl, piperazinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, isothiazolidinyl, tetrahydrothienyl, tetrahydrofuryl, thiazinanyl, thiadiazinanyl, and dioxanyl; wherein the saturated heterocyclic ring is optionally substituted with from 1 to 3 substituents each of which is independently -C₁₋₄ alkyl or oxo; or

- (iii) a heteroaromatic ring selected from the group consisting of pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, furanyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isooxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, and thiadiazolyl; wherein the heteroaromatic ring is optionally substituted with from 1 to 3 substituents each of which is independently halogen, -C₁₋₄ alkyl, or -O-C₁₋₄ alkyl;




or a pharmaceutically acceptable salt thereof.





- 10 17. A compound selected from the group consisting of:







5









5







5





5





5

and pharmaceutically acceptable salts thereof.

18. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to either claim 1 or claim 13, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

5 19. A method of inhibiting HIV integrase in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of the compound according to either claim 1 or claim 13, or a pharmaceutically acceptable salt thereof.

10 20. A method for preventing or treating infection by HIV or for preventing, treating or delaying the onset of AIDS in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of the compound according to either claim 1 or claim 13, or a pharmaceutically acceptable salt thereof.

15 21. The method according to claim 20, wherein the compound is administered in combination with a therapeutically effective amount of at least one antiviral selected from the group consisting of HIV protease inhibitors, non-nucleoside HIV reverse transcriptase inhibitors and nucleoside HIV reverse
20 transcriptase inhibitors.

22. A pharmaceutical composition which comprises the product prepared by combining an effective amount of a compound according to either claim 1 or claim 13, or a pharmaceutically acceptable salt thereof, and a pharmaceutically
25 acceptable carrier.

30 23. A combination useful for inhibiting HIV integrase, for treating or preventing infection by HIV, or for preventing, treating or delaying the onset of AIDS, which is a therapeutically effective amount of a compound according to either claim 1 or claim 13, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of an HIV infection/AIDS antiviral agent selected from the group consisting of HIV protease inhibitors, non-nucleoside HIV reverse transcriptase inhibitors and nucleoside HIV reverse transcriptase inhibitors.